NCT04724850

Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura

Observational Study About the Characteristics and Evolution of Patients Diagnosed With COVID-19 in Extremadura

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 440 (actual)
• Sponsor: Juan Fernando Masa Jiménez · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

At the end of January 2020, the international community was informed of the presence of a new viral disease that started in Wuhan (China) and spread rapidly throughout the world. The identified virus belonged to the coronavirus family (SARS-CoV-2) and the disease was named COVID-19. Today there are more than 2 million people diagnosed in Spain and more than 40 thousand in Extremadura. The partial knowledge about the development, evolution of the affected citizenship and their prognosis both early and late makes it necessary to analyze in depth their global and particular characteristics. We will carry out a multicenter, observational, descriptive, cross-sectional and longitudinal study of patients diagnosed with SARS-CoV-2 virus infection in the Community of Extremadura to determine the effectiveness of drug treatments and the clinical and evolutionary characteristics of these patients and the different factors that may influence its evolution.

Detailed description

Epidemiological, socio-sanitary, clinical, analytical and radiological data will be collected retrospectively and prospectively from all patients diagnosed with COVID-19 without hospital admission in our community from the start of the pandemic and for one year from the start of the study. These data will be obtained mainly from the clinical history and collected in the data collection notebooks and electronic base designed for the study for subsequent analysis. The data collection period will be one year, estimating a sample of 5,000 patients. In addition, patients included in the study prospectively will be asked for consent to collect a blood sample for freezing and storage in the Biobank of Extremadura and subsequent use to determine biomarkers and genetics. The present study will be carried out in accordance with the observational National Post-Authorization Study (EPA) for medicines for human use proposed by Valdecilla Health Research Institute (IDIVAL), the main objective of which is to determine the effectiveness of the pharmacological treatments currently used in COVID-19.

Conditions

• Coronavirus Disease 2019

Timeline

• Start date: 2020-07-14
• Primary completion: 2022-12-20
• Completion: 2022-12-30
• First posted: 2021-01-26
• Last updated: 2024-05-08

Locations

1 site across 1 country: Spain